News Release

Cost Effective Prescribing For Duodenal Ulcers

Peer-Reviewed Publication

BMJ

(Varying efficacy of helicobacter pylori eradication regimens: cost effectiveness study using a decision analysis model)

The value of eradicating helicobacter pylori in duodenal ulcer disease is well established but small differences in the efficacy of antibiotic regimens can have a big influence on the comparative cost effectiveness of eradication strategies.

In a commentary, Delany and Hobbs point out that prescribing for dyspepsia is now the largest single area of cost for primary care, £500 million per year in the United Kingdom in 1996. Although this covers non-ulcer dyspepsia as well as peptic ulcer disease, the size of the bill underlines the rationale for making cost-effectiveness part of the eradication strategy for H pylori.

Contact :

Prof Richard Logan, Department of Public Health and Epidemiology, University of Nottingham, Nottingham NG7 2UH

t: +44 (0)115 970 9315 f: +44 (0)115 970 9316 e-mail : richard.logan@nottingham.ac.uk

###



Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.